Open AccessLonger recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
Author(s) -
Satoh Tendo,
Koie Takuya,
Horiguchi Hirotaka,
Tokui Noriko,
Narita Satoshi,
Ohyama Chikara
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1181
Subject(s) - temsirolimus , medicine , sorafenib , renal cell carcinoma , oncology , overall survival , discovery and development of mtor inhibitors , progression free survival , pi3k/akt/mtor pathway , hepatocellular carcinoma , apoptosis , biochemistry , chemistry
Key Clinical Message Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second‐line therapy in patients with metastatic renal cell carcinoma ( mRCC ). Only a few patients achieved complete responses, and the median progression‐free survival rate remains short. We report one patient with mRCC who had a continuing response to temsirolimus.